TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Abdominal Nerve Blockade in Chronic Heart Failure.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of heart failure (HF)~* Symptomatic with dyspnea~* On a stable HF drug regimen~Exclusion Criteria:~* Ongoing treatment with oral anticoagulation other than aspirin~* Immunosuppressive medications for solid organ transplant~* Acute MI (STEMI or Type I NSTEMI) within 7 days~* Systolic blood pressure \< 90 mmHg or \>180 mmHg~* Infiltrative cardiomyopathy or constrictive cardiomyopathy~* Chronic kidney disease stage 5~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Regional nerve anesthesia (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Testosterone Gel on Carbohydrate and Lipid Metabolism In Elderly Obese Men

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Entry Criteria:~* Men \> 60 years of age~* Total testosterone \< 300 ng/dL~* Waist circumference \>102 cm~* Fasting insulin level \> 18 U/L~Exclusion Criteria:~* PSA \> 4.1, symptoms of obstructive uropathy (AUA score \> 14), unexplained prostate nodule or gland firmness~* Hematocrit \> 50%~* Malignancy other than cutaneous cancers~* Sleep apnea requiring CPAP~* History of myocardial infarction, angina or stroke within the previous 6 months~* Clinical diagnosis of diabetes or FPG \> 126 mg/dL~* Hypothyroidism not controlled to euthyroid levels with medication for at least 3 months~* LDL-C \>160 mg/dL~* Transaminases \> 1.5X ULN~* Systemic anticoagulation with warfarin~* Active progressive resistance training~* Dieting for weight loss~* Active inflammatory condition (e.g. rheumatoid arthritis)~* Use of any anabolic agent (e.g. growth hormone, testosterone precursor, anabolic steroid)or cytokine therapy in the proceeding 12 months

- Gender: MALE
- Minimum Age: 60 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- Single arm (Type: EXPERIMENTAL): Open label treatment without masking with each participant serving as his own control. Measurements are compared before and after treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Clareon Vivity/Vivity Toric

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Understand and sign an approved Informed Consent form~* Previously implanted in both eyes with Clareon Vivity/Clareon Vivity Toric or Clareon Monofocal/Clareon Toric IOLs for at least 3 months and up to 6 months (90 to 180 days) after second eye implant.~* Other protocol-defined inclusion criteria may apply.~Key Exclusion Criteria:~* History of clinically significant ocular co-morbidities that would affect surgical outcomes based on investigator expert medical opinion.~* Subjects who were targeted to monovision defined as ≥ 1.50 Diopter (D) of anisometropia.~* Clinically significant PCO (posterior capsule opacification) affecting vision.~* Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Clareon Vivity/Vivity Toric (Type: EXPERIMENTAL): Previous implantation in both eyes with Clareon Vivity/Vivity Toric Extended Vision IOL (intraocular lens), with previous implantation defined as 90-180 days post second eye implantation
- Clareon Monofocal/Clareon Toric (Type: ACTIVE_COMPARATOR): Previous implantation in both eyes with Clareon Monofocal/Clareon Toric IOL (intraocular lens), with previous implantation defined as 90-180 days post second eye implantation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Effectiveness of a Multifocal Intraocular Lens (IOL)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Visual potential of 20/30 or better in each study eye~* Preoperative BCDVA worse than Snellen 20/40 or worse than 20/30 in the presence of glare (as measured using a Snellen chart with BAT at medium)~* Naturally dilated pupil size (in dim light) \> 4.0 mm (with no dilation medications) for each study eye~* Preoperative corneal astigmatism of 1.0 D or less~Exclusion Criteria:~* Use of systemic or ocular medications that may affect vision (the use of any miotic agent is specifically contraindicated)~* Acute or chronic disease or illness that would increase the operative risk or confound the study outcome(s),(e.g., diabetes mellitus, immunocompromised, connective tissue disease, etc.)~* Uncontrolled systemic or ocular disease~* History of ocular trauma or prior ocular surgery or subjects expected to require retinal laser treatment or other surgical intervention~* Presence of ocular pathology other than cataract such as:~  * Amblyopia or strabismus~ * Corneal abnormalities~ * Pupil abnormalities~ * Capsule or zonule abnormalities~ * Intraocular inflammation~ * Known pathology that may affect visual acuity and/or are predicted to cause future acuity losses to a level of 20/30 or worse (e.g. macular degeneration)~* Requiring an intraocular lens outside the study diopter range~* Contact lens usage prior to study procedure (time interval dependent upon contact lens type)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Tecnis Multifocal IOL group (Type: EXPERIMENTAL): Subjects implanted bilaterally with the Tecnis Multifocal IOL. Participants were enrolled in this arm in the original study and also in the expansion study. Outcomes of the first eye of each subject were analyzed for the primary study endpoints.
- CeeOn 911A monofocal control IOL group (Type: ACTIVE_COMPARATOR): Subjects implanted bilaterally with the CeeOn 911A monofocal IOL. Participants enrolled in this arm only in the original study; no control subjects were enrolled in the expansion study. Outcomes of the first eye of each subject were analyzed for the primary study endpoints.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with locally advanced or metastatic solid tumors who have received three or less prior lines of systemic chemotherapy~* Participants must have relapsed or had progressive disease following standard of care treatment with chemotherapy prior to enrollment, or intolerant to prior standard of care treatment with chemotherapy~* Normal cardiac conduction and function as documented on a 12-lead electrocardiogram~* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1~* Adequate organ function as evidenced by laboratory tests~* Able to receive dexamethasone or its equivalent~* Agrees to protocol-defined use of effective contraception~Exclusion Criteria:~* Participants treated with more than three prior chemotherapy regimens (including adjuvant therapy)~* Previous exposure to trabectedin~* Central nervous system (CNS) metastasis~* Known hypersensitivity to any of the components of the trabectedin intravenous formulation or dexamethasone~* Heart rhythm disturbances, unusual T wave and U wave (if present) morphology, blood pressure outside of normal range, a history of cardiac failure, myocardial infarction, or cardiomyopathy, or a history of additional risk factors for torsade de pointes (eg, heart failure, electrolyte abnormalities, family history of Long QT Syndrome)~* Participants who at screening are on medication that is known to prolong the QT interval or who is on CYP3A4 inhibitors or inducers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Trabectedin (Type: EXPERIMENTAL): 3-hour placebo intravenous infusion on Day 1 and trabectedin 1.3 mg/m2 3-hour intravenous infusion on Day 2 (single-blind). Patients may continue treatment with trabectedin until clinical benefit or drug is commercially available (open-label).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years of age or older~2. Diagnosis of OAB and associated symptoms of UUI and qualify with at least 3 episodes of mild, moderate, or severe urgency demonstrated on a 3-day urinary voiding diary~3. Experiencing UUI symptoms for at least 3 months~4. No prior treatment with anticholinergics/antimuscarinics or beta 3-agonists medications to treat OAB~5. Willing and able to accurately complete voiding diaries and questionnaires, attend visits, and comply with the study protocol~6. Willing and able to provide signed and dated informed consent~Exclusion Criteria:~1. Have received anticholinergics/antimuscarinics or beta 3-agonists medications to treat OAB or advanced therapy treatment options for OAB (botulinum toxin injections, sacral neuromodulation, or percutaneous tibial nerve stimulation/neuromodulation)~2. Primary stress incontinence or mixed incontinence where the stress component overrides the urge component~3. Have implantable pacemakers or implantable defibrillators~4. Use of transcutaneous electrical nerve stimulation (TENS) in pelvic region, back or legs~5. Women who are pregnant or planning to become pregnant during the course of the study~6. Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol~7. Nerve damage that could impact either tibial nerve or pelvic floor function.~8. Subjects prone to excessive bleeding~9. Inadequate skin integrity in the area of PTNM needle placement~10. History of diabetes unless the diabetes is well-controlled through diet and/or medications~11. Have symptomatic urinary tract infection (UTI)~12. Participation in any research study involving or impacting gynecologic, urinary or renal function within the 4-week period prior to or plans to participate during study enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NURO System PTNM Therapy (Type: OTHER): Subjects will undergo 12 PTNM therapy sessions, administered weekly, utilizing the NURO system.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Participant has a well-documented clinical history of epilepsy.~* Participant has a clinical diagnosis of Tuberous Sclerosis Complex (TSC) according to the criteria agreed by the 2012 International TSC Consensus Conference.~* All medications or interventions for epilepsy (including ketogenic diet and any neurostimulation devices for epilepsy) must have been stable for 1 month prior to screening and the participant is willing to maintain a stable regimen throughout the trial.~Key Exclusion Criteria:~* Participant has a history of pseudo-seizures.~* Participant has clinically significant unstable medical conditions other than epilepsy.~* Participant has an illness in the 4 weeks prior to screening or randomization, other than epilepsy, which in the opinion of the investigator could affect seizure frequency.~* Participant has undergone general anesthetic in the 4 weeks prior to screening or randomization.~* Participant has undergone surgery for epilepsy in the 6 months prior to screening.~* Participant is being considered for epilepsy surgery or any procedure involving general anesthesia.~* Participant has been taking felbamate for less than 1 year prior to screening.~* Participant is taking an oral mTOR inhibitor.~* Participant has any known or suspected hypersensitivity to cannabinoids or any of the excipients of the Investigational Medicinal Product (IMP), such as sesame oil.~* Participant has any history of suicidal behavior or any suicidal ideation of type 4 or 5 on the C-SSRS in the last month or at screening.~* Participant is currently using or has in the past used recreational or medicinal cannabis, or cannabinoid-based medications, within the 3 months prior to screening and is unwilling to abstain for the duration for the study.~* Participant has tumor growth which, in the opinion of the Investigator, could affect the primary endpoint.~* Participant has significantly impaired hepatic function at the screening or randomization visit~* Participant has received an IMP within the 12 weeks prior to the screening visit.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 25 mg/kg/day GWP42003-P (Type: EXPERIMENTAL): 100 mg/mL GWP42003-P oral solution taken twice daily (morning and evening).
- 50 mg/kg/day GWP42003-P (Type: EXPERIMENTAL): 100 mg/mL GWP42003-P oral solution taken twice daily (morning and evening).
- Placebo (Type: PLACEBO_COMPARATOR): Placebo oral solution matching 100 mg/mL GWP42003-P.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Regional Prophylactic Vancomycin in Revision Total Knee Replacement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Revision total knee arthroplasty~* Informed consent given~Exclusion Criteria:~* Current treatment with IV Vancomycin within the preceding 7 days~* Previous hypersensitivity to vancomycin~* Significant cardiac or respiratory abnormality~* Contraindications to using the intraosseous vascular access system (EZ-IO)~* Sepsis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vancomycin 500mg intraosseous (Type: EXPERIMENTAL): Vancomycin 500mg is given via intraosseous regional administration (IORA) into a proximal tibial cannula, after tourniquet inflation and immediately prior to skin incision.
- Vancomycin 1g IV (Type: ACTIVE_COMPARATOR): Vancomycin 1g is administered via forearm vein, given over a one-hour infusion, timed to finish approximately 30 minutes prior to tourniquet inflation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of a Diabetes Camp on Glycemic Control Among Children and Adolescents Living With Type 1 Diabetes in Cameroon

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Children living with type 1 diabetes and enrolled in the Changing Diabetes in Children project.~* Regular follow-up at the Yaoundé Central Hospital.~* Aged between 6 and 23 years old.~* Informed consent signed by parents or guardians prior to enrollment in the CDiC project allowing investigators of the project to used data for research.~* Informed consent forms signed by parents or guardians before participation to the 2013 camp in Yaoundé.~Exclusion Criteria:~* Nonattendance of the routinely follow-up visits at the CDiC clinic Yaoundé both at 3 and 12 months after camp.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 23 Years
- Healthy Volunteers: f

Study Arms:
- Insulin therapy and diabetes education (Type: OTHER): Children and adolescents living with type 1 diabetes already on insulin therapy received collective diabetes education during a five days camp.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of NN1250 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 diabetes mellitus for at least 12 months~* Current treatment with any basal bolus insulin for at least 12 months~* HbA1c below or equal to 10.0%~* Body Mass Index (BMI) below or equal to 35.0 kg/m\^2~* For Japan only: Minimum age is 20 years~* For the extension trial only: Completed the six-month treatment period in trial NN1250-3585 (NCT01074268)~Exclusion Criteria:~* Use of any other antidiabetic drug than insulin within the last 3 months~* Cardiovascular disease within the last 6 months~* Uncontrolled treated/untreated severe hypertension~* Recurrent severe hypoglycemia or hypoglycemic unawareness or hospitalisation for diabetic ketoacidosis during the previous 6 months~* Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate contraceptive measures~* Cancer and medical history of cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IDeg OD (Type: EXPERIMENTAL): None
- IDet (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ezetimibe and Atorvastatin vs. Atorvastatin in Patients Age 65 and Older at High Risk for Coronary Heart Disease (CHD)(0653-112)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is age 65 or older~* Patient is willing to maintain cholesterol lowering diet~* Patient has hyperlipidemia with LDL level greater than 70 mg/dl or 100 mg/dl depending on their CHD risk category~Exclusion Criteria:~* A condition which, in the opinion of the investigator, would pose a risk to the patient or interfere with participation in the study~* Patient is unlikely to be compliant in taking study medication~* Patient with chronic or unstable medical condition~* Patient is taking unstable doses of medication~* Patient drinks more than 2 alcoholic drinks per day~* Patient has elevations in certain laboratory values (CK, AST, ALT)

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete